This case illustrates that BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor therapy may represent a viable option for neoadjuvant therapy in locally advanced BRAF V600E mutant NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.